The purpose of this study is to find out if an investigational treatment called P-BCMA-ALLO1 is safe and will help treat people with Multiple Myeloma. The study is also being done to determine what dose is safe and effective to treat Multiple Myeloma.

The purpose of this study is to determine the recommended ABBV-400 dose when ABBV-400 is given alone (monotherapy) in Stage 1, and to assess if ABBV-400 monotherapy is a safe and effective treatment compared to the standard of care (SOC) LONSURF [Trifluridine and Tipiracil] plus Bevacizumab in subjects with c-Met overexpressed (level of c-Met protein in your tumor cells is increased) uncontrolled metastatic colorectal cancer in Stage 2 of the study plan.

Do you have metastatic colorectal cancer? Does your cancer lack certain mutations? If so, you might be eligible to take part in a trial to look at the effects of an investigational anticancer drug given with normal therapy.

Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have thyroid cancer? If so, you may be eligible to participate in a research study to see which targeted therapy will work better to prolong the time until your tumor grows or spreads, after initial treatment.

This clinical trial is studying two different investigational treatments for patients with a blood disorder called myelodysplastic syndromes (MDS) who have a specific genetic mutation (IDH1) and have not been treated with certain drugs before. The study will compare the effects of two study drugs, Ivosidenib (IVO) and Azacitidine (AZA), given separately, to see how well they help patients. Researchers will track how many patients experience improvements, how long the treatment effects last, and overall survival.

Have you been diagnosed with early-stage breast cancer or ductal carcinoma in situ (DCIS) and have undergone breast conserving surgery (lumpectomy). If so this may be the research for you!! You may be able to take part in a research study to evaluate the effects of the tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with the WBI, as opposed to after the WBI.

Do you have incurable, metastatic, or recurrent head and neck squamous cell carcinoma? If so, you may be able to participate in a study to evaluate the addition of the anti-cancer drug, Cetuximab, to standard of care treatment.

The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

This study is testing a new drug called MRTX1719. The main goal is to find the best dose of the drug to use in future studies. The study will also look at what side effects the drug may cause and how often they happen. Researchers will also measure how quickly the drug is absorbed into the bloodstream and how fast the body gets rid of it. Additionally, they will check how well MRTX1719 works against cancer.